Literature DB >> 24503899

A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo.

Luyue Chen1, Kailiang Zhang1, Zhendong Shi1, Anling Zhang1, Zhifan Jia1, Guangxiu Wang1, Peiyu Pu1, Chunsheng Kang1, Lei Han1.   

Abstract

microRNA (miRNA) sponges are RNA molecules with repeated miRNA binding sequences that can sequester miRNAs from their endogenous target mRNAs, and a stably expressed miRNA sponge is particularly valuable for long-term loss-of-function studies in vitro and in vivo. Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and is characterized by extraordinarily angiogenic, invasive and migratory capabilities, hallmark features that make the disease incurable. Nonetheless, improvements in clinical treatment and a better understanding of the underlying molecular mechanisms have been achieved within the past few decades. miR-23b has previously been found to function as a tumor oncogene in GBM. In the present study, we employed an microRNA sponge that was forcibly expressed using a lentiviral vector to knock down the expression of miR-23b in vitro and in vivo and assessed the pleiotropic effects on glioma angiogenesis, invasion and migration. We demonstrated that the inhibition of miR-23b in glioma cell lines and orthotopic tumor mouse models resulted in a reduction in tumor malignancy, through the downregulation of HIF-1α, β-catenin, MMP2, MMP9, VEGF and ZEB1 and increased expression of VHL and E-cadherin. Therefore, we suggest that this miR-23b sponge could be developed into a promising anticancer therapy either alone or in combination with current targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24503899     DOI: 10.3892/or.2014.3012

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  26 in total

Review 1.  Sponging of cellular proteins by viral RNAs.

Authors:  Phillida A Charley; Jeffrey Wilusz
Journal:  Curr Opin Virol       Date:  2014-09-17       Impact factor: 7.090

2.  MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2.

Authors:  Fan Yang; Wei Wang; Chunhui Zhou; Wenjin Xi; Lu Yuan; Xu Chen; Yufang Li; Angang Yang; Jianning Zhang; Tao Wang
Journal:  Tumour Biol       Date:  2015-03-04

Review 3.  MicroRNA Therapeutics: the Next Magic Bullet?

Authors:  Bridget Simonson; Saumya Das
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

4.  Generation of MiRNA sponge constructs targeting multiple MiRNAs.

Authors:  Junjin Jie; Danni Liu; Yifan Wang; Qiong Wu; Tingting Wu; Rong Fang
Journal:  J Clin Lab Anal       Date:  2022-06-06       Impact factor: 3.124

5.  ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation.

Authors:  Guiyan Xu; Jian Yi Li
Journal:  J Neurooncol       Date:  2015-11-02       Impact factor: 4.130

Review 6.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

Review 7.  Glioblastoma: molecular pathways, stem cells and therapeutic targets.

Authors:  Meena Jhanwar-Uniyal; Michael Labagnara; Marissa Friedman; Amanda Kwasnicki; Raj Murali
Journal:  Cancers (Basel)       Date:  2015-03-25       Impact factor: 6.639

8.  microRNA-23b regulates the expression of inflammatory factors in vascular endothelial cells during sepsis.

Authors:  Ming Wu; Jian-Teng Gu; Bin Yi; Zhong-Zhi Tang; Guo-Cai Tao
Journal:  Exp Ther Med       Date:  2015-01-28       Impact factor: 2.447

9.  MicroRNA-23b Inhibits the Proliferation and Migration of Heat-Denatured Fibroblasts by Targeting Smad3.

Authors:  Xipeng Zhang; Jie Yang; Jiming Zhao; Pihong Zhang; Xiaoyuan Huang
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

10.  Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases.

Authors:  Matthew S Alexander; Louis M Kunkel
Journal:  J Neuromuscul Dis       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.